Awada, G.; Schwarze, J.K.; Tijtgat, J.; Fasolino, G.; Everaert, H.; Neyns, B.
A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRASQ61R/K/L Mutant Melanoma (TraMel-WT). Cancers 2021, 13, 2010.
https://doi.org/10.3390/cancers13092010
AMA Style
Awada G, Schwarze JK, Tijtgat J, Fasolino G, Everaert H, Neyns B.
A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRASQ61R/K/L Mutant Melanoma (TraMel-WT). Cancers. 2021; 13(9):2010.
https://doi.org/10.3390/cancers13092010
Chicago/Turabian Style
Awada, Gil, Julia Katharina Schwarze, Jens Tijtgat, Giuseppe Fasolino, Hendrik Everaert, and Bart Neyns.
2021. "A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRASQ61R/K/L Mutant Melanoma (TraMel-WT)" Cancers 13, no. 9: 2010.
https://doi.org/10.3390/cancers13092010
APA Style
Awada, G., Schwarze, J. K., Tijtgat, J., Fasolino, G., Everaert, H., & Neyns, B.
(2021). A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRASQ61R/K/L Mutant Melanoma (TraMel-WT). Cancers, 13(9), 2010.
https://doi.org/10.3390/cancers13092010